Todd Tushla | Vice President, Investor Relations |
Kevin Gorman | Chief Executive Officer |
Matt Abernethy | Chief Financial Officer |
Eiry Roberts | Chief Medical Officer |
Eric Benevich | Chief Commercial Officer |
Kyle Gano | Chief Business Development and Strategy Officer |
Biren Amin | Jefferies |
Paul Matteis | Stifel |
Tazeen Ahmad | Bank of America |
Josh Schimmer | Evercore |
Laura Christianson | Cowen |
Brian Skorney | Baird |
Tessa Romero | JPMorgan |
Paul Choi | Goldman Sachs |
Jeff Hung | Morgan Stanley |
Vamil Divan | Mizuho Securities |
Yatin Suneja | Guggenheim partners |
Joseph Stringer | Needham & Company |
Charles Duncan | Cantor Fitzgerald |
Marc Goodman | SVB Leerink |
David Amsellem | Piper Sandler |
Good day, everyone, and welcome to today's Neurocrine Biosciences Reports Fourth Quarter and Year End 2020 Results. At this time, all participants are in a listen-only mode. Later, you'll have the opportunity to ask questions during the question-and-answer session. [Operator Instructions] Please note, this call may be recorded and I will be standing by if you need any assistance. It is now my pleasure to turn the conference over to Vice President of Investor Relations, Todd Tushla.